Haloperidol, Droperidol, Ondansetron in Cannabis Hyperemesis
Phase 3
Terminated
- Conditions
- Cyclic Vomiting Syndrome
- Interventions
- Registration Number
- NCT05065567
- Lead Sponsor
- Spectrum Health - Lakeland
- Brief Summary
The purpose of this study is to compare two commonly used agents for the treatment of cyclic vomiting to see if one agent is inferior to the other in time to improvement in symptoms, need for repeat or rescue medications, treatment failures and complications/side effects.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 32
Inclusion Criteria
- adult patients with clinical diagnosis of cyclic vomiting in the ED
Exclusion Criteria
- pregnancy, allergy to any of the study medicines
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description ondansetron Ondansetron 8mg these patients will receive 8mg IV ondansetron haloperidol Haloperidol these patients will receive 5mg IM haloperidol droperidol Droperidol these patients will receive 2.5mg IV droperidol
- Primary Outcome Measures
Name Time Method Abdominal Pain 48 hours change in abdominal pain on 0 (no pain) through 10 (worse possible pain) on a visual analog scale
Nausea 48 hours change in nausea on 0 (none) through 10 (worse possible nausea) on a scale
- Secondary Outcome Measures
Name Time Method Treatment Success 48 hours both abdominal pain and nausea scores under 2 (none or minimal)
Trial Locations
- Locations (1)
Lakeland Regional Healthcare
🇺🇸Saint Joseph, Michigan, United States